[New combination chemotherapy in urological cancers]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 31, 2000
Summary
New combination therapies show promise for difficult-to-treat urological cancers like metastatic renal cell carcinoma (RCC) and bladder transitional cell carcinoma (TCC). Further large-scale trials are needed to confirm efficacy beyond current standards.
Area of Science:
- Uro-oncology
- Medical Oncology
- Clinical Trials
Background:
- Current treatments for metastatic renal cell carcinoma (RCC) and bladder transitional cell carcinoma (TCC) have limitations, with only up to 20% achieving complete response.
- For bladder TCC, M-VAC chemotherapy has been a standard for over a decade without significant improvement.
- Hormone-refractory prostate cancer also presents therapeutic challenges.
Purpose of the Study:
- To review novel combination chemotherapies aimed at overcoming limitations of current urological cancer treatments.
- To explore new therapeutic strategies for metastatic RCC, TCC, and hormone-refractory prostate cancer.
Main Methods:
- Review of recent clinical trials investigating new combination chemotherapy regimens.
- Focus on specific combinations for different urological malignancies: IL-2/IFN-alpha/5-fluorouracil for RCC; paclitaxel/gemcitabine and cisplatin/carboplatin for TCC; paclitaxel/docetaxel and estramustine for prostate cancer.
Main Results:
- Initial trial results for the discussed combination therapies are promising.
- The combination of IL-2, IFN-alpha, and 5-fluorouracil is being investigated for RCC.
- New regimens for TCC and hormone-refractory prostate cancer also show encouraging early outcomes.
Conclusions:
- Novel combination chemotherapies demonstrate potential to improve outcomes in urological cancers.
- While initial results are promising, large-scale clinical trials are essential to validate these findings.
- Further research is needed to establish the efficacy and safety of these new treatment strategies.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
04:45Integration of Electroporation in Urological Practice: Design and Evaluation of a New Transurethral Electrode
Published on: March 20, 2026
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...